- AstraZeneca and Merck said Japanese regulators had approved their ovarian cancer drug as a front-line therapy following positive clinical trial results.

The approval by the Japanese Ministry of Health, Labour and Welfare was based on data from the pivotal Phase III SOLO-1 trial which tested the cancer drug, Lynparza, as maintenance monotherapy compared with placebo in patients with advanced ovarian cancer following 1st-line platinum-based chemotherapy.

The Phase III SOLO-1 trial showed that 60% of patients receiving the cancer drug Lynparza remained free of disease progression after three years compared with just 27% on placebo.

Story provided by